Fractyl New Preclinical Data from Rejuva® Smart GLP-1 Pancreatic Gene Therapy Platform at ADA

Fractyl Health (NASDAQ: GUTS), a metabolic therapeutics company, will present new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association's 85th Scientific Sessions. The presentation, scheduled for June 22, 2025, will showcase results from a study titled 'Single-Dose GLP-1–Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat–Fed Mice.' The poster session will take place at the ADA conference in Chicago from June 20-23, 2025, with the specific presentation scheduled for 12:30-1:30 PM in Hall F1. The data will be made available on Fractyl's website after the conference presentation.

https://www.stocktitan.net/news/GUTS/fractyl-health-to-present-new-preclinical-data-from-its-rejuva-smart-6vsoyam47pf2.html